Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646005 | 0.80 | KDM4E (0.50) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL235080 | 0.79 | KDM4E (0.65) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL425926 | 0.76 | GLA (0.47) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL524469 | 0.76 | GLA (0.47) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL2595940 | 0.76 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL2817042 | 0.76 | KDM4E (0.52) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL21623672 | 0.76 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL11856358 | 0.76 | KDM4E (0.70) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL10913328 | 0.76 | KDM4E (0.70) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL5354826 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | claimed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | claimed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885SMN1; SMN2 1511/4885KEAP1 262/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 1709/4885SMN1; SMN2 869/4885KEAP1 382/4885 |
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | KDM4E 2115/4885SMN1; SMN2 4097/4885KEAP1 2681/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885SMN1; SMN2 1511/4885KEAP1 262/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM4E 2714/4885SMN1; SMN2 1511/4885KEAP1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.